The efficacy of the traditional medicine preparation of dodder (Cuscuta campestris Yunck.) and polypody (Polypodium vulgare) in patients with obsessive-compulsive disorde

The efficacy of the traditional medicine preparation of dodder (Cuscuta campestris Yunck.) and polypody (Polypodium vulgare) in patients with obsessive-compulsive disorder: A double-blind clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200112046092N1

Enrollment

Registered

2020-07-11

Start date

2020-06-21

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: Herbal drug include Basfaj (Polypodium vulgare) rhizome and aftimon (Cuscuta campestris) The components of the drug are 250 mg tablets (150 mg of Besfaij rhizome po

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age range 18 to 70 years Practicing obsessive compulsive disorder Be treated with Fluvoxamine No alcohol or drugs Lack of physical illnesses such as: diabetes, hypertension, cardiovascular problems A score above 21 on the Yale-Brown-OCS criterion Absence of other psychiatric disorders such as bipolar and psychotic disorders Absence of mental retardation Non-pregnancy and lactation

Exclusion criteria

Exclusion criteria: Drug intolerance Necessity to take psychiatric drugs other than fluvoxamine or to take measures such as ECT

Design outcomes

Primary

Measure	Time frame
Severity of obsessive symptoms. Timepoint: Before starting the treatment and after 4 and 8 weeks of taking the drug, the participants are asked to complete the Yale-Brown questionnaire. Method of measurement: Yale-Brown questionnaire.;Quality of life. Timepoint: Before starting the treatment and after 4 and 8 weeks of taking the drug, the participants are asked to complete the quality of life questionnaire. Method of measurement: quality of life questionnaire.	—

Measure

Time frame

Severity of obsessive symptoms. Timepoint: Before starting the treatment and after 4 and 8 weeks of taking the drug, the participants are asked to complete the Yale-Brown questionnaire. Method of measurement: Yale-Brown questionnaire.;Quality of life. Timepoint: Before starting the treatment and after 4 and 8 weeks of taking the drug, the participants are asked to complete the quality of life questionnaire. Method of measurement: quality of life questionnaire.

—

Secondary

Measure	Time frame
Determining the effect of gender on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown.;Determining the effect of age on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown.;Determining the effect of education on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown.	—

Measure

Time frame

Determining the effect of gender on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown.;Determining the effect of age on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown.;Determining the effect of education on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehnaz Bakhshi Nejad

Kerman University of Medical Sciences

behnaz.bn1984@gmail.com+98 34 3211 0360

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026